Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Investor Presentation (February 2025)
17 slides from Glucotrack's investor presentation, February 2025
Slide 1: Advancing Diabetes Management
Advancing Diabetes Management Next Generation Continuous Blood Glucose Monitoring February 2025 © Copyright 2024. All rights reserved. Glucotrack.
Slide 2: Important Disclaimers
Important Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: Glucotrack: Imagining the Future of Glucose Monitoring
Glucotrack: Imagining the Future of Glucose Monitoring Our mission is to push the boundaries of glucose sensor technology. Our fully implantable Continuous Blood Glucose Monitoring (CBGM) technology offers patients a less intrusive, more accurate way to better manage their diabetes and improve qual
Slide 4: Next Generation CGM: A Compelling Investment Opportunity
Next Generation CGM: A Compelling Investment Opportunity Differentiated product and Large and expanding Multiple near-term world class team addressable market milestones • Differentiated best-in-class • $9.8B global CGM market1 • First in-human studies began CBGM with potential to opportunity in Q4
Slide 5: Diabetes is a Growing Healthcare Problem
Diabetes is a Growing Healthcare Problem 38 million in the U.S. suffer from diabetes, or 1 in 10 Americans, and is Global Prevalence and Health Expenditure1 the 8th leading cause of death2 (in millions) $1,200 900 In the U.S., > $1 in $4 healthcare dollars 800 $1,000 are spent on people with diabete
Slide 6: CGM: The Standard of Care for Diabetes Management
CGM: The Standard of Care for Diabetes Management CGM Global Quarterly Revenue ($ millions) • Since its introduction in 1999, CGM has become the standard of care for diabetes management in key segments • $9.8 billion global CGM market in 20231 (approximately 50% U.S.) • $12 billion estimated global
Slide 7: Reimbursed CGM is a Severely Underpenetrated Market
Reimbursed CGM is a Severely Underpenetrated Market ~$5B U.S. ~$5B untapped market in U.S. market 20231 Market leaders Glucotrack has the 38M people in 10M total reached 50%2 50%product / the US have patients: penetration; technology to diabetes CGM is standard technology unable capture the of care
Slide 8: Barriers to Further CGM Penetration
Barriers to Further CGM Penetration Demand for increased longevity: short Unaddressed Patient Needs Growing in Importance sensor life (max 15 days) requires frequent replacement and recalibration Longer sensor wear 44% 64% Dissatisfaction with on-body experience: system can be uncomfortable and 39%
Slide 9: Introducing A Novel Approach to Managing Glucose with Best-in-Class Potential
Introducing A Novel Approach to Managing Glucose with Best-in-Class Potential • Combines the best of glucose monitoring and cardiac monitoring technology in one device • Uses FDA-approved materials and processes to reduce development costs, development risks, and time to market = Transmitter Sensor
Slide 10: The Next Generation Innovation in Glucose Monitoring
The Next Generation Innovation in Glucose Monitoring Unsurpassed longevity: 20-minute outpatient, local anesthesia placement every 3 years (vs. 15 days) 100% implantable and no on-body device improves patient comfort and compliance Uses blood glucose (the gold standard) vs. interstitial fluid glucos
Slide 11: Development and Regulatory Timeline
Development and Regulatory Timeline Short-term Long-term US Pivotal FDA OUS first-in- US Pivotal study Submission OUS first-in- human study study begins enrollment (1-year data) human study begins* begins ends 2024 2025 2026 2027 2028 IDE pre- 1-year data US Pivotal US launch US Pilot from long-term
Slide 12: Proven Execution with Seasoned Leadership Team
Proven Execution with Seasoned Leadership Team Paul V. Goode, PhD Peter Wulff, MBA • President & CEO • Chief Financial Officer • Glucose monitoring (MiniMed, • Diagnostics (Biological Dynamics) Dexcom) • Structural heart disease • Implantable cardiac devices (Guidant, (JenaValve Technology) Impulse
Slide 13: Summary: A Compelling Investment Opportunity
Summary: A Compelling Investment Opportunity Differentiated product and Large and expanding Multiple near-term world class team addressable market milestones • Differentiated best-in-class • $9.8B global CGM market1 • First in-human studies began CBGM with potential to opportunity in Q4 2024 elevate
Slide 14: APPENDIX
APPENDIX © Copyright 2024. All rights reserved. Glucotrack.
Slide 15: Current Publications
Current Publications In Vivo Evaluation of Novel Long-Term Intravascular Continuous Blood Glucose Monitor in a Chronic Ovine Model Authors: Paul V Goode, PhD; Michael Talcott, DVM; JP Thrower, PhD; Timothy L Routh, M Eng.; Jose Garcia; Stephen T Tapsak; Samantha Wakil, PhD; Mark A Tapsak, PhD Poster
Slide 16: Experienced, Dedicated Board of Directors
Experienced, Dedicated Board of Directors Mr. Malavé brings more than 30 years of leadership in the MedTech industry, primarily in diabetes management. He has extensive expertise in product development, operations, Luis J. Malave, Chair marketing, strategic partnerships, and FDA regulatory strategy.
Slide 17: Thank You
Thank You 17 © Copyright 2024. All rights reserved. Glucotrack.